All News
‘Strong’ treatment predictions in inflammatory myositis
Presented at EULAR 2026 London, Brepocitinib dual TYK2/JAK1 inhibitor with successful Phase 3 VALOR trial demonstrating significant improvement in skin and muscle symptoms in dermatomyositis (DM).
Read Article
📋 Do 2025 ASAS-SPARTAN criteria classify fewer real-world axSpA patients?
Data from the RABBIT-SpA registry (n=2,236) confirms:
67% vs 73% with 2009 criteria
Clinical arm rarely fulfilled
#POS0190 #EULAR2026 @RheumNow https://t.co/HYie4w8c6r
Nelly ZIADE 🍀 Nellziade ( View Tweet)
🔍 Do posterior element lesions progress over 10 years in axSpA?
Data from the DESIR inception cohort (n=320) says RARELY!
But baseline PE inflammation raises facet ankylosis risk ~70-fold
#POS0189 #EULAR2026 @RheumNow https://t.co/PdwlPGjKqK
Nelly ZIADE 🍀 Nellziade ( View Tweet)
🔮 Can polygenic risk scores predict PsA timing in psoriasis?
Another GWAS study (n=703) says YES!
70-SNP model achieves AUC 0.843 for predicting PsA onset <10 vs >10 years
#POS0088 #EULAR2026 @RheumNow https://t.co/wI4Jy8Yu2A
Nelly ZIADE 🍀 Nellziade ( View Tweet)
🧪 Can genetics predict TNFi response in PsA?
OUTPASS GWAS (n=329): High BMI, comorbidities & novel XKR4 locus linked to non-response at 6 months
#POS0087 #EULAR2026 @rheumnow
Nelly ZIADE 🍀 Nellziade ( View Tweet)
CyTOF reveals significant sexual dimorphism in monocyte populations in active #axSpA
Women show reduced classical and non-classical monocytes vs healthy controls. Men do not show the same pattern.
Sex is not just a demographic variable in AxSpA it is also an immunological one.
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
From Skepticism to Reconsideration: 4‑Year CAR‑T Outcomes in Lupus
Chimeric antigen receptor (CAR) T‑cell therapy, long established in hematologic malignancies, is now emerging as a transformative approach in systemic lupus erythematosus (SLE), a disease historically managed https://t.co/Dmmw90XnuF
Dr. John Cush RheumNow ( View Tweet)
DAY 1 & 2 Recap: EULAR 2026 Highlights https://t.co/uVMerChWN6
Links:
Dr. John Cush RheumNow ( View Tweet)
Progress of biologics/targeted therapy in SLE
We are in a transformative era for SLE, for clinicians and patients. Four targeted therapies are now licensed: belimumab (nephritis and non‑renal), voclosporin and obinutuzumab (nephritis), and anifrolumab (non‑renal). Many agents https://t.co/BuFCmj1hQd
Dr. John Cush RheumNow ( View Tweet)
@RheumNow HOT #Obesity session (7)
📢A call for action
Current RMD treatments ignore obesity:
They all target immune response but miss the metabolic-inflammatory loop
Breaking that cycle may be the missing piece
Obesity must be part of every rheumatology plan
#EULAR2026 @rheumnow
Nelly ZIADE 🍀 Nellziade ( View Tweet)
☂️What is an umbrella meta-analysis?
It's a meta-analysis of meta-analyses ☔️
⬇️This one showed the effect of diet supplementation on several RA outcomes
Unfortunately, most studies have low levels of evidence
#umbrella #rainy_London #EULAR2026 @rheumnow https://t.co/kYPchXEexn
Nelly ZIADE 🍀 Nellziade ( View Tweet)
🔥 TOGETHER-PsA (OP069) #EULAR2026 #EULARbest Ixekizumab + Tirzepatide vs IXE alone in PsA with obesity/overweight: ✅ Primary endpoint (ACR50 + ≥10% wt loss at W36): 31.7% vs. 0.8% (p<0.001) ✅ ACR50: 33.5% vs. 20.4% ✅ MDA: 26.3% vs. 15.3% (p=0.026) @rheumnow @DrLauraCoates https://t.co/6wh3S6khXw
Nelly ZIADE 🍀 Nellziade ( View Tweet)
Ivarmacitinib (selective JAK1 inhibitor) significantly improved ASAS40 vs placebo in nr-#axSpA(39.7% vs 24.8%; p=0.006) at 12 weeks, sustained to 24 weeks. Another oral option for non-radiographic disease. Abstr OP0237 @RheumNow #EULAR2026
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
DR JOHN STONE gives Overview
Of
#IgG4
New non B cell depleter
#obexelimab N=194 in RCT
To add to B cell depletion w
#Inebilizumab
Off label but used also
#Rituximab
#steroids
#Immunesuppressives
Other investigational drugs
Ex #JAKi
#EULAR2026 @RheumNow
#OP018 #RULARbest https://t.co/Y4saGYcdww
Links:
Janet Pope Janetbirdope ( View Tweet)
🔬 Can baseline T cell phenotype predict PsA treatment response?
COLIPSO cohort (n=17): YES!
Higher Treg & activated CD4+ cells predict DAPSA & joint improvement
#POS0083 #EULAR2026 @RheumNow https://t.co/UIs6LXAWAY
Nelly ZIADE 🍀 Nellziade ( View Tweet)
🧬 Does spine vs knee enthesis differ immunologically?
Translational scRNAseq study: YES!
Spine produces more IL-23 but shows attenuated IL-17 response vs knee
#POS0084 #EULAR2026 @RheumNow https://t.co/itFrLEXSzZ
Nelly ZIADE 🍀 Nellziade ( View Tweet)
🔍 Are 2025 ASAS-SPARTAN criteria valid in early axSpA?
SPACE cohort (n=669):
HIGH specificity (97.5%) but LOWER sensitivity (60%) vs 2009 criteria (83%)
#OP0239 #EULAR2026 @RheumNow https://t.co/9wNbtcbP0l
Nelly ZIADE 🍀 Nellziade ( View Tweet)
A Field Whose Time Has Come: Launching the EULAR Study Group on Geriatric Rheumatology
EULAR launches a Study Group on Geriatric Rheumatology — clinics increasingly serve older patients with multimorbidity, polypharmacy, frailty, cognitive and functional limits, yet research
Dr. John Cush RheumNow ( View Tweet)
🎗️ Do targeted therapies raise cancer risk in SpA?
French nationwide cohort (n=56,591): NO
In fact, prolonged exposure REDUCES risk (wHR 0.86), especially haematological.
#OP0238 #EULAR2026 @RheumNow https://t.co/dDveAmWpdX
Nelly ZIADE 🍀 Nellziade ( View Tweet)
💉 Does ivarmacitinib (selective #JAK1i work in nr-axSpA?
Phase 3 RCT (n=304):
ASAS40 39.7% vs 24.8% placebo at week 12
with sustained benefit at week 24
#OP0237 #EULAR2026 @RheumNow https://t.co/kofXnPp6qQ
Nelly ZIADE 🍀 Nellziade ( View Tweet)
